{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T23:32:38Z","timestamp":1768951958032,"version":"3.49.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Sleep"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mast cell-mediated inflammation has been proposed as a potential contributor to neuroinflammatory insomnia and dysautonomia, but objective clinical documentation remains limited. Histamine and related immune mediators can disrupt circadian rhythm, arousal systems, and autonomic stability. Conventional pharmacological therapies for sleep restoration often fail to address these inflammatory mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A previously healthy and active 74-year-old male presented with post-viral dysautonomia and severe, treatment-refractory insomnia accompanied by persistent sneezing and ocular irritation suggestive of histamine reactivity. Despite optimal CPAP use and multiple pharmacological trials for sleep disturbance (zolpidem, trazodone, gabapentin, diazepam, lemborexant), Oura Ring data demonstrated persistently low sleep scores, often in the 30\u201340 range, and minimal REM and deep sleep. Routine laboratory studies (CBC, CMP, thyroid, cortisol, testosterone) were normal except for mildly low DHEA-S, consistent with chronic inflammatory stress. Following evaluation by a tertiary sleep specialist who suggested daytime stimulant therapy (declined by the patient), a targeted supportive regimen was initiated to promote physiologic recovery and restore sleep architecture. This included phosphatidylcholine, alpha-GPC, coenzyme Q10, cyproheptadine (2\u20134 mg at qHS) and removal of scented household products. Sleep metrics improved within 24 h, with Oura sleep scores increasing to 75+ from a 10-month period characterized by nightly scores often in the 30\u201340 range and remained stable thereafter. At 4-week follow-up, lingering daytime fatigue and patient-reported cognitive fog prompted additional dietary modification to a low-histamine pattern and the addition of loratadine (10 mg AM) and famotidine (20 mg BID).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome<\/jats:title>\n                    <jats:p>Within several days, the patient reported marked improvement in energy, cognition, and overall functional capacity, following nearly a year of functional incapacitation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates a reversible form of inflammatory insomnia and fatigue, likely mediated by mast cell-driven histamine activity. A multi-component intervention targeting histamine pathways, including antihistamine therapy, environmental modification, and dietary adjustment, was associated with rapid and sustained normalization of objective sleep metrics in this patient. These findings highlight the importance of evaluating immune and inflammatory contributors in patients with refractory insomnia and support further investigation of mast cell-related pathways in translational sleep medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frsle.2025.1736866","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:11:47Z","timestamp":1768907507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case of post-viral inflammatory insomnia: observed sleep restoration associated with histamine-targeted interventions and implications for mast cell pathways"],"prefix":"10.3389","volume":"4","author":[{"given":"Amanda Jill","family":"Meckes","sequence":"first","affiliation":[{"name":"RestoreWellnessRx","place":["Baton Rouge, LA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James William","family":"Meckes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"723888","DOI":"10.3389\/fped.2021.712413","article-title":"Safety of cyproheptadine, an orexigenic drug: analysis of the French pharmacovigilance database","volume":"9","author":"Bertrand","year":"2021","journal-title":"Front. Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.sleep.2023.09.034","article-title":"The association of insomnia with long COVID: an international collaborative study (ICOSS-II)","volume":"112","author":"Chen","year":"2023","journal-title":"Sleep Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1384852","DOI":"10.3389\/fimmu.2024.1445867","article-title":"Role and mechanisms of mast cells in brain disorders","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.5664\/jcsm.11420","article-title":"Prevalence and associations of insomnia after COVID-19 infection","volume":"21","author":"Kadl","year":"2025","journal-title":"J. Clin. Sleep Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/life14020164","article-title":"Combination of H1 and H2 histamine receptor antagonists: current knowledge and perspectives of a classic treatment strategy","volume":"14","author":"Kou","year":"2024","journal-title":"Life"},{"key":"B6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.alit.2022.06.008","article-title":"Time will tell about mast cells: circadian control of mast cell activation","volume":"71","author":"Nakao","year":"2022","journal-title":"Allergol. Int."},{"key":"B7","unstructured":"\u201cCyproheptadine.\u201d\n          \n          LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.\n          \n          2017"},{"key":"B8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/7854_2022_359","article-title":"Brain mast cells in sleep and behavioral regulation","volume":"59","author":"Nishino","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"A16","DOI":"10.1289\/ehp.119-a16","article-title":"Indoor air quality: scented products emit a bouquet of VOCs","volume":"119","author":"Potera","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"B10","doi-asserted-by":"publisher","first-page":"zsy183","DOI":"10.1093\/sleep\/zsy183","article-title":"Histamine: neural circuits and new medications","volume":"42","author":"Scammell","year":"2019","journal-title":"Sleep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s11869-016-0442-z","article-title":"Fragranced consumer products: exposures and effects worldwide","volume":"9","author":"Steinemann","year":"2016","journal-title":"Air Qual. Atmos. Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2024.01.020","article-title":"Validity and reliability of the Oura Ring Generation 3 (Gen3) with Oura sleep staging algorithm 2.0 when compared to multi-night ambulatory polysomnography: a validation study of 96 participants and 421,045 epochs","volume":"115","author":"Svensson","year":"2024","journal-title":"Sleep Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"8929","DOI":"10.1523\/JNEUROSCI.1032-19.2019","article-title":"Reassessing the role of histaminergic tuberomammillary neurons in arousal control","volume":"39","author":"Venner","year":"2019","journal-title":"J. Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jaip.2019.08.022","article-title":"Mast cell activation syndrome: tools for diagnosis and differential diagnosis","volume":"8","author":"Weiler","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bph.15220","article-title":"Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness","volume":"178","author":"Yoshikawa","year":"2020","journal-title":"Br. J. Pharmacol."}],"container-title":["Frontiers in Sleep"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frsle.2025.1736866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:11:49Z","timestamp":1768907509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frsle.2025.1736866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":15,"alternative-id":["10.3389\/frsle.2025.1736866"],"URL":"https:\/\/doi.org\/10.3389\/frsle.2025.1736866","relation":{},"ISSN":["2813-2890"],"issn-type":[{"value":"2813-2890","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"article-number":"1736866"}}